CurrentBlue KCPolicy POL-PP-283

General Inflammation Testing (CRP and ESR) Coverage Criteria

Customize your policy alerts

Sign up for Blue KC Policy POL-PP-283 alerts

Get alerted when Policy POL-PP-283 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy governing reimbursement and preferred use of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) testing for diagnosed or suspected inflammatory conditions for Blue KC lines of business and provider types specified.

Policy Summary

PayerBlue KC

PolicyGeneral Inflammation Testing (CRP and ESR) Coverage Criteria

Policy CodePolicy POL-PP-283

Change TypeNo material changes

Effective DateJul 1, 2025

Next Review DateJul 1, 2026

Key ActionOrder CRP preferentially when both CRP and ESR are considered; if both are ordered where only one is allowed, only CRP will be approved.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

4procedure codes listed

CRP

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentBlue KCPolicy POL-PP-283

General Inflammation Testing (CRP and ESR) Coverage Criteria

Customize your policy alerts

Sign up for Blue KC Policy POL-PP-283 alerts

Get alerted when Policy POL-PP-283 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerBlue KC

PolicyGeneral Inflammation Testing (CRP and ESR) Coverage Criteria

Policy CodePolicy POL-PP-283

Change TypeNo material changes

Effective DateJul 1, 2025

Next Review DateJul 1, 2026

Key ActionOrder CRP preferentially when both CRP and ESR are considered; if both are ordered where only one is allowed, only CRP will be approved.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

4procedure codes listed

CRP

Coverage Criteria for CRP and ESR

Covered indications (by condition)

Measurement of CRP and/or ESR may be reimbursed for specified diagnosed or suspected inflammatory conditions when criteria below are met. CRP is preferred when either is allowed; if both are ordered where only one is allowed, only CRP will be approved.

Allowed indications list: Testing allowed for the specific conditions listed in Notes: acute and chronic urticaria; acute hematogenous osteomyelitis (AHO); acute phase inflammation; ankylosing spondylitis; arthritis; Castleman's disease; general inflammation; Hodgkin lymphoma; irritable bowel syndrome; large vessel vasculitis (giant cell arteritis, Takayasu arteritis); nonradiographic axial spondyloarthritis; polymyalgia rheumatica; periprosthetic joint infections (PJI); rheumatoid arthritis; systemic lupus erythematosus; T-cell lymphomas.

See Notes for test preference (CRP and/or ESR) by condition and condition-specific frequency guidance.

Frequency and monitoring intervals

Where condition-specific frequency guidance is provided, follow the stated intervals.

Frequency guidance examples: Examples from Notes: Acute hematogenous osteomyelitis (AHO): CRP preferred; to confirm diagnosis; every 2–3 days during early therapy; then weekly until normalization or clear trend to normalization. Rheumatoid arthritis: CRP or ESR; prior to treatment; every 1–3 months during active disease; annually when disease is inactive. Hodgkin lymphoma: ESR preferred; every 3–6 months for 1–2 years, every 6–12 months for the next 3 years, then annually. Polymyalgia rheumatica: CRP or ESR; at initial diagnosis; every 3 months during long-term steroid therapy. Large vessel vasculitis: CRP and ESR; to confirm diagnosis; every 1–3 months during the first year; every 3–6 months thereafter. Periprosthetic joint infections (PJI): CRP and ESR; frequency = Not specified. Many other conditions in Notes list have 'Not specified' intervals—follow the Notes for full details.

Follow condition-specific intervals in Notes; when Not Specified (NS) no interval is provided.

Measurement of C-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR) may be reimbursed only for the specified diagnosed or suspected inflammatory conditions listed in the policy. Coverage is contingent on the member's benefit coverage at the time of the request and applicable coding and claims adjudication. For individuals without a diagnosed inflammatory condition, measurement of ESR may not be reimbursed. Additionally, measurement of CRP and/or ESR during a general exam without abnormal findings may not be reimbursed.

Routine or screening ordering of these tests is not supported by the policy. Specifically, ordering ESR for individuals without a diagnosed inflammatory condition is considered not reimbursed, and routine ordering of CRP or ESR during general examinations without abnormal findings is not reimbursed. Note that when either CRP or ESR is allowed for a condition, CRP is the preferred biomarker; if both CRP and ESR are submitted for a condition where only one is allowed, only CRP will be approved.

Condition-specific Covered Indications

See condition list

See the Notes for test preference (CRP and/or ESR) for each listed condition; when either CRP or ESR is allowed, CRP is preferred.

Conditions enumerated (see Notes): Acute and chronic urticaria; Acute hematogenous osteomyelitis (AHO); Acute phase inflammation; Ankylosing spondylitis; Arthritis; Castleman's disease; General inflammation; Hodgkin lymphoma; Irritable bowel syndrome; Large vessel vasculitis (giant cell arteritis, Takayasu arteritis); Nonradiographic axial spondyloarthritis; Polymyalgia rheumatica; Periprosthetic joint infections (PJI); Rheumatoid arthritis; Systemic lupus erythematosus; T-cell lymphomas.

Refer to Notes for each condition's test preference (CRP, ESR, or both) and any specified frequency guidance.

Test preference rules: When either CRP or ESR are allowed for a condition, CRP is the preferred biomarker. If both CRP and ESR are ordered at the same time for a condition where only CRP or ESR is allowed, only CRP will be approved.

Per Note 1.

Frequency and Monitoring Limits by Condition

CRP and/or ESR — Condition-specific frequency guidance

Acute Hematogenous Osteomyelitis (AHO)Test preference = CRP; Frequency = to confirm diagnosis; every 2–3 days during early therapy; weekly until normalization or clear trend toward normalization.

Rheumatoid arthritisTest preference = CRP or ESR; Frequency = prior to treatment; every 1–3 months during active disease; annually when disease is inactive.

Hodgkin lymphomaTest preference = ESR; Frequency = every 3–6 months for 1–2 years; every 6–12 months for the next 3 years; annually thereafter.

Polymyalgia rheumaticaTest preference = CRP or ESR; Frequency = at initial diagnosis; every 3 months during long-term steroid therapy.

Large vessel vasculitisTest preference = CRP and ESR; Frequency = to confirm diagnosis; every 1–3 months during the first year; every 3–6 months thereafter.

Procedure Codes

Covered CPT CodesCPTCovered

85651	Sedimentation rate, erythrocyte; non-automated
85652	Sedimentation rate, erythrocyte; automated
86140	C-reactive protein
86141	C-reactive protein; high sensitivity (hsCRP)

Provider Actions and Billing Guidance

Documentation Required

Coverage determination dependencies

Coverage of any service is determined by date of service, the member's eligibility and benefit limits for the service(s) rendered, all terms of the Provider Service Agreement, and applicable coding rules and guidelines. Final payment is subject to claims adjudication and industry-standard edits. Confirm member coverage and medical necessity with the appropriate Blue KC provider hotline when needed.

Affected: CRP and ESR testing claims
Operational note: Coverage depends on submitted coding and the member's benefit at the time of service
Contact: Blue KC Provider Hotline (Commercial) 816-395-3929; ACA Provider Hotline 866-859-3822; Medicare Advantage Provider Hotline 866-508-7140

Prior Authorization

Prior authorization — check member benefits

Prior authorization — reimbursement depends on benefit coverage at time of request; there is no universal prior authorization for CRP/ESR indicated in this policy. Submit requests in accordance with the member's plan requirements.

Ordering Requirements

Note

Ordering depends on benefit/date of service; no provider-type restriction

Coverage is contingent on the member's benefit at the time of service and the date of service; the policy document does not restrict which provider types may order CRP or ESR testing.

Not Covered Services

Not covered: Measurement of ESR for individuals who do not have a diagnosed inflammatory condition. Measurement of CRP and/or ESR performed as part of a general physical exam when there are no abnormal findings is also not covered. These situations may result in denial of reimbursement.

Background

Inflammation is a physiological response to tissue injury and a variety of disorders such as arthritis, systemic lupus erythematosus, and infection. Laboratory measures used to detect and monitor inflammation include acute phase reactants such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). CRP testing may be performed using conventional or high-sensitivity methods. In clinical practice these tests are used in different contexts; when the policy allows either marker, CRP is the preferred biomarker.

Definitions

inv-11: CRP — C-reactive protein

DefinitionC-reactive protein (CRP) is an acute phase reactant released during inflammation; conventional CRP and high-sensitivity CRP (hsCRP) are allowed testing methods.

Preferred useWhen either CRP or ESR are allowed for a condition, CRP is the preferred biomarker; if both are ordered where only one is allowed, only CRP will be approved.

Clinical roleCRP can be used to detect and monitor inflammation across conditions (e.g., infection, arthritis) and for serial monitoring during therapy.

inv-12: ESR — Erythrocyte sedimentation rate

DefinitionErythrocyte sedimentation rate (ESR) is a laboratory measure using the sedimentation of red blood cells to assess inflammation.

Test roleESR is an alternative measure of inflammation for specified conditions (e.g., Hodgkin lymphoma, some rheumatologic diseases) when designated in the condition-specific notes.